Urolog. pro Praxi, 2005; 2: 62-66

TRENDS IN MEDICAL TREATMENT OF PROSTATE CANCER

doc. MUDr. Ladislav Jarolím CSc
Urologická klinika 2. LF UK a FN Motol, Praha

Current trends in medical treatment of prostate canter are focused on neoadjuvant and adjuvant androgen deprivation in clinical localized androgen dependent prostate cancer minimizing side-effects, use of taxanes in the treatment of hormone-refractory disease and on adjuvant prevention of bone metastases using bisphosphonates. Early androgen blocade using monotherapy, intermittent androgen suppression leading to side effect reductions and parenteral bisphosphonates are preferred.

Keywords: Key words: prostate, cancer, advanced prostate cancer, androgen deprivation, hormone-refractory disease.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jarolím L. TRENDS IN MEDICAL TREATMENT OF PROSTATE CANCER. Urol. praxi. 2005;6(2):62-66.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amling CL, Bergstralh EJ, Blute ML, Zincke H. Prostate cancer progression rate following radical prostatectomy in patients with seminal vesicle involvement. J Urol 1998; 159: 149 (493). Go to PubMed...
    2. Bagley CM, Lane RF, Blasko JC, Grimm PD, Ragde H, Cobb OE. Adjuvant chemohormonal therapy of high risk prostate carcinoma. Cancer 2002; 94: 2728-2732. Go to original source... Go to PubMed...
    3. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156: 1511-1516. Go to original source...
    4. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156: 1064-1068. Go to original source... Go to PubMed...
    5. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002; 360:103-108. Go to original source... Go to PubMed...
    6. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80 Suppl.: 1588-1594. Go to original source...
    7. Conti G, Cretarola E, Boccardo F, Battaglia M, Di Tonno P, Bertaccini A, De Antoni P, Zattoni F, Galassi P, Durand F. Tamoxifen is a safe and effective in preventing gynecomastia and brest pain induced by bicalutamide monotherapy of prostate cancer and does not alter treatment efficiency. Eur Urol 2004; 3, suppl.: 58, 221. Go to original source...
    8. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003; 170: 21-27. Go to original source... Go to PubMed...
    9. Crook JM, Ludgate C, Lim J, Malone S, Eapen L, Perry G, Bowen J, Robertson S, Lockwood G. Multicenter canadian phase iii randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation prior to conventional dose radiotherapy for clinically localized prostate cancer J Urol 2004; 171: 312 (1182). Go to original source...
    10. Damber JE. Decreasing mortality rates for prostate cancer: possible role of hormonal therapy? BJU International 2004; 93: 695-701. Go to original source... Go to PubMed...
    11. Dušek P, Hyršl L, Kawaciuk I. Kompletní intermitentní androgenní blokáda v léčbě karcinomu prostaty, Vybrané otázky z onkologie V, Galén 2002: 45-46.
    12. Dušek P, Jarolím L, Kawaciuk I, Hyršl L. Chemoterapie hormonálně independentního karcinomu prostaty. in J. Abrahámová: Vybrané otázky onkologie VII. Galén 2003; 47-48.
    13. Dušek P, Jarolím L, Kawaciuk I, Hyršl L. Výsledky chemoterapie u hormonálně independentního karcinomu prostaty. Česká urologie 2003; 7: 22-23.
    14. Eaton AC, Makris A, Makris A. Once weekly tamoxifen in the prevention of gynaaecomastia and breast pain secondary to bicalutamide therapy. J Urol 2004; 171: 282 (1069). Go to original source...
    15. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100. Go to original source... Go to PubMed...
    16. Green JR. Bisphosphonates in cancer therapy. Curr Opin Oncol 2002; 14: 609-615. Go to original source... Go to PubMed...
    17. Grossman ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen- refractory prostate cancer. J Natl Cancer Inst 2001; 93: 1687-1897. Go to original source... Go to PubMed...
    18. Iversen P, McLeod DG, See WA, Wirth MP, Morris T, Carroll K. Bicalutamide 150 mg for early non-metastatic prostate cancer in patients who would otherwise undergo watchful waiting: latest results at a median 5.4 years' follow-up. J Urol 2004; 171: 280 (1061). Go to original source...
    19. Iversen P. Bicalutamide 150 mg in addition to standard care in patients with early, non-metastatic prostate cancer: results from the SPCG-6 study at a median follow-up of 5.3 years. J Urol 2004; 171: 311-312 (1181). Go to original source... Go to PubMed...
    20. Kawaciuk I, Dušek P, Teršípová L. Předběžné výsledky intermitentní androgenní suprese u karcinomu prostaty. Česká urology 2002; 6: 74-75.
    21. Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology 2003; 62: 866-871. Go to original source... Go to PubMed...
    22. Klein E, Dreicer R, Magi-Galluzzi C, Zhou M, Zippe CD, Fergany A, Ulchaker JC, Rothaermel J, Reuther AM. Neoadjuvant docetaxel prior to radical prostatectomy induces a significant PSA response in men with locally advanced prostate cancer: results of a phase II trial J Urol 2004; 171: 306 (1060).
    23. Langenstroer P, Poulton T, Kramer B,Cutting B, Amling CL, Lance RS, Thrasher JB. Multi-institutional evaluation of depo-provera for the treatment of hot flashes associated with androgen ablation for prostate cancer J Urol 2004; 171: 384 (1457). Go to original source...
    24. Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M. The new bisphosphonate, ZOMETA (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20 Suppl. 2: 45-54. Go to original source... Go to PubMed...
    25. Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer 2000; 88: 6-14. Go to original source...
    26. Matoušková M, Hanuš M. Intermitentní androgenní suprese (IAS) v léčbě karcinomu prostaty. Česká urologie, 2003; 7: 11-15.
    27. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED,Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-1784. Go to original source... Go to PubMed...
    28. Millikan RE, Brown M, Moomey B, Logothetis CJ. Preliminary results of a phase III trial of hormonal therapy vs. Chemohormonal therapy as initial treatment for non-localized prostate cancer J Urol 2004; 171: 384 (1459). Go to original source...
    29. Nelius T, AJ Quesada AJ, Alfranca A, Yap RL, Zaichuk T, Redondo JM, Volpertet OV. Treatment with doxorubicin and a truncated TSP1 peptide synergistically inhibits tumor angiogenesis in prostate cancer. J Urol 2004; 171: 293 (1112). Go to original source...
    30. Oh WK, Kanthoff PW: Treatment of locally advanced prostate cancer: is chemotherapy the next step? J Clin Oncol 1999; 17: 3664-3675. Go to original source... Go to PubMed...
    31. Parkinson RJ, Simms MS, Broome P, Humphreys JE, Bishop MC. A accination strategy for the long-term suppression of androgens in advanced prostate cancer. Eur Urol 2004; 45: 171-175. Go to original source... Go to PubMed...
    32. Porkka KP, Visakopi T. Molecular mechanisms of prostate cancer. Eur Urol 2004; 45: 683-691. Go to original source... Go to PubMed...
    33. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597. Go to original source... Go to PubMed...
    34. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002; 346: 653-661. Go to original source... Go to PubMed...
    35. Roberts SG, Blute ML, Bergstralh EJ. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001; 76: 576-581. Go to original source...
    36. Rodan GA, Fleisch HA: Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97: 2692-2696. Go to original source... Go to PubMed...
    37. Saad F, Gleason D, Murray R, Venner P, Tchekmedyian S, Lacombe L, Chin J, Vinholes J, Goas JA, Cen BL, Seaman J. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal compliacations in patients with advanced prostate cancer metastatic to bone. J Urol 2003; 169: 394 (1472).
    38. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468. Go to original source... Go to PubMed...
    39. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.47. Go to original source... Go to PubMed...
    40. Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. Eur Urol, 2004; 45: 26-34. Go to original source... Go to PubMed...
    41. See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur Urol 2003; 44: 512-518. Go to original source... Go to PubMed...
    42. See WA, Iversen P, McLeod DG, Wirth MP, Carroll K, Morris T. Bicalutamide 150 mg in addition to standard care significantly improves prostate specific antigen progression-free survival in patients with early, non-metastatic prostate cancer: median 5.4 years' follow-up. J Urol 2004; 171: 280-281 (1062). Go to original source...
    43. See WA, Iversen p, McLeod DG, Wirth MP, Morris T, Carroll K. Bicalutamide 150 mg alone or as adjuvant to standard care significantly improves progression-free survival in patients with early, non-metastatic prostate cancer (median 5.4 years' follow-up). J Urol 2004; 171: 214 (810). Go to original source...
    44. Slovin SF, Gardner JP, Morrissey DM, Gardner JP, Donovan GP, Surowitz KG, Olson WC, Scher HI, Israel RJ. Phase I trial of an adjuvanted recombinant soluble prostate-specific membrane antigen (RSPSMA) vaccine J Urol 2004; 171: 286-287 (1087). Go to original source...
    45. Tazi H, Manunta A, Rodriguez A, Patard JJ, Lobel B, Guillé F. Spinal Cord Compression in Metastatic Prostate Cancer. Eur Urol 2003; 44: 527-532. Go to original source... Go to PubMed...
    46. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parenteral androgen-dependent cancer cells. Cancer J 2000; 6: 220-233.
    47. Tunn U, Kurek R, Kienle E, Maubach L. Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy (RP). J Urol 2004; 171: 384 (1458). Go to original source... Go to PubMed...
    48. Vaishampayan U, Hussain M. Adjuvant chemo/hormonal therapy trials for locally advanced prostate cancer. Curr Oncol Rep 2000; 2: 402-408. Go to original source... Go to PubMed...
    49. Wilkinson S, Chodak G. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. Eur Urol 2004; 45: 581-585. Go to original source... Go to PubMed...
    50. Wirth M, Iversen P, McLeod DG, See WA, Morris C, Morris T, Carroll K. Bacalutamide (Casodex) 150 mg as adjuvant to radical prostatectomy significantly increases progression free survival in patients with early non-metastatic prostate cancer: analysis at a median follow-up of 5,4 year. Eur Urol 2004; 3, Suppl.: 48 (No 181). Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.